cyrilzakka/clinical-trials huggingface dataset:
Lower Extremity Elevation to Minimize Hemodynamic Instability During Induction of General Anesthesia

The purpose of this study is to determine if lower extremity elevation (LEE) will reduce the incidence of postinduction hypotension, to compare the utilization of vasoactive medications after induction in patients with LEE and patients without LEE and to determine if LEE will increase measured cardiac output


Eligibility Criteria:
Inclusion Criteria:

* American Society of Anesthesiologists (ASA)3 or lower
* Patients requiring general anesthesia

Exclusion Criteria:

* Allergic reaction to drugs commonly used for general anesthesia including fentanyl, midazolam, propofol, ephedrine and phenylephrine
* Pregnant women
* Requiring rapid sequence induction
* Prisoners
* Patient refusal
* Emergency Surgery
Office Blood Pressure Measurement With an Automated Device

The investigators plan to determine if the sequence of blood pressure measurements from the sitting position to the table and vice versa has an impact on the measurements.

The investigators plan to measure blood pressure (BP) in 30 consecutive individuals presenting to the St. Elizabeth Boardman Family Health Center. The sample will include patients presenting for their scheduled appointment. Following informed consent (see attached informed consent form), the participants will be randomly assigned to one of two groups. In group A, the sequence of BP measurements will be table position (TP) followed by recommended chair position (RCP) and then, after a 30-minutes rest, the BP will be measured again in the reverse sequence, RCP then TP. In group B, the sequence will begin with BP measurements in the RCP then TP, followed by 30-minutes rest and then measurements will be repeated in the reverse order. The assignment of participants to groups A and B will be random. The BP will be measured twice in each of the positions described above, according the the accepted standard technique, using a digital blood pressure monitor, the OMRON HEM-907 XL.

Eligibility Criteria:
Inclusion Criteria:

* Patients presenting to the Family Medicine Center age between 18 and 80

Exclusion Criteria:

* Decline to participate for any reason
* Experiencing acute pain or febrile illness
* Pregnant
* Inability to get on the examination table
* Atrial fibrillation, arrhythmia or tachycardia
Practicality of Intermittent Fasting and Its Effect on Markers of Aging and Oxidative Stress

Healthy volunteers will be recruited to participate in a ten-week double-blinded crossover trial. The trial will consist of two, three-week periods of intermittent fasting, where subjects receive either antioxidant supplementation or placebo, the ordering of which will be randomly determined. A one-week preconditioning will precede each invention period, and a two week "wash-out" period will follow the first intervention period. Serum-based assays will be performed to assess levels of reactive oxidant species, antioxidant genes, sirtuins, and markers of mitochondrial biogenesis and aging.

The investigators hypothesize that an intermittent fasting diet in healthy young volunteers will improve these markers of cellular aging and that these beneficial effects will be abrogated by the supplementation of antioxidants. This study is a proof-of-principle study that will shed light on the mechanism and effects of IF as an anti-aging dietary intervention in the absence of weight loss. It will inform the design of dietary interventions that are both effective in improving markers of aging and feasible for patients to practice on a long-term basis.


Eligibility Criteria:
Inclusion Criteria:

* Body mass index in the range of 20.0-30.0 kg/m2;
* Age between 19 and 30;
* Stable weight (change \<±10%) for 3 months immediately prior to the study
* No history of metabolic disorders (e.g. non-diabetic), cardiovascular disease, or thyroid dysfunction
* No past or present eating disorders
* No acute or chronic inflammatory disorder
* No more than moderate physical activity (i.e.,\<3 hour/week of light exercise sessions for the past 3 months)
* No current medications to regulate blood sugar or lipids
* Not donated blood within 56 days of study start date
* No food allergies
* No dietary restrictions (e.g. vegetarianism and vegan)
* No heavy drinking (more than 15 drinks/week)
* No use of tobacco or recreational drugs within past 3 months
* Access to a microwave or stove
* Access to refrigeration

Exclusion Criteria:

* Inflexibility of schedule such that subject cannot attend blood draw appointments
* Unwillingness to pick-up and eat only study-provided food during the 8 weeks in which it is provided and for unwillingness to abstain from travel (\>48hrs) during these same 8 weeks of the trial (travel is permitted during wash-out period)
* Unwillingness to abstain from tobacco, alcohol, recreational drugs, resveratrol or antioxidant supplements (other than study-provided) for the duration of study
* Women who are pregnant, breast-feeding or trying to become pregnant
Anti-inflammatory H1 Antihistamines Allergic Rhinitis

The main purpose of the treatment of persistent allergic rhinitis is to improve symptoms and patients' quality of life and prevent the development of asthma. Therapeutic strategies also target a reduction of pro-inflammatory mediators released from activated cells, including mast cells and epithelial cells. The presence of allergic inflammation in nasal mucosa may increase the risk of asthma occurrence, especially in patients with persistent allergic rhinitis. H1 antihistamines are widely recommended in all types of allergic rhinitis, regardless of symptom severity or persistence. They control all of the symptoms, but to a lesser extent nasal congestion. New generation agents, such as levocetirizine and desloratadine, possess anti-inflammatory properties, reducing allergic inflammation.

Allergic rhinitis is characterized by a chronic inflammation of nasal mucosa and represents a risk factor for asthma occurrence. H1 antihistamines reduce the rhinitis' symptoms, but some compounds may have anti-inflammatory properties.

We evaluated the plasmatic level of some cytokines in patients with persistent allergic rhinitis (PAR) and their evolution after 4-week treatment with H1 antihistamines and the risk of asthma after 1.5 year.

Eighty-five patients with PAR and 30 healthy volunteers were included in the study. The patients with PAR were randomly divided into 2 groups: 41 patients treated with desloratadine 5 mg/day and 44 patients under levocetirizine 5 mg/day for 4 weeks.

The clinical evaluation include the presence and severity of allergic rhinitis' symptoms: rhinorrhea, nasal congestion, sneezing, nasal and ocular itching and duration of the disease.

Each symptom was evaluated on scale from 0 to 3 (0=absent, 1=mild, 2=moderate, 3=severe) and after that we calculated the total symptoms score (TSS).

A TSS\<6 means a mild rhinitis, while a TSS\> 6 represented a moderate severe one.

The patients were clinically evaluated after 1.5 year to determine the possible onset of bronchial asthma.

The biological evaluation means determination of total IgE and plasmatic level of IL-1 beta, IL-6, IL-8 and TNF alpha.

Clinical and biological evaluation were performed before and after treatment

Eligibility Criteria:
Inclusion Criteria:

* persistent allergic rhinitis

Exclusion Criteria:

* the presence of asthma or nasal polyps,
* acute and chronic upper respiratory infections,
* administration of intranasal or systemic corticosteroids or H1 antihistamines in the past 30 days.
Pilot Clinical Evaluation of the RHEA Vital Sign Vigilance System in Hospital Patients

This study compares both of the investigational device and reference device to the gold standard Patient Monitor of the accuracy of heart rate and respiratory rate monitoring. The primary variables for the analysis of heart rate (HR) and respiratory rate (RR) are each of the overall mean roots mean square difference (RMSD). Results of the investigational device and reference device compared with the patient monitor is evaluated to see if there are equivalent. Motion and bed exit accuracy will be evaluated by comparing with the manual observation.

Tests (periods 1 and 2), one of the contact-free devices will be used to monitor the HR and RR, while being compared with the Patient Monitor. The RHEA investigational device and reference device will be used to monitor the same subject at different times, as the sensors of the two devices are placed at a similar location of the bed. HR and RR will be recorded for all three devices.

The primary hypotheses for HR, are as follows:

Adults HO: μ = 3.25 vs. HA: μ \< 3.25

The primary hypotheses for RR, are as follows:

Adults HO: μ = 2.25 vs. HA: μ \< 2.25 where μ represents the population mean HR or RR. If the upper bound of the confidence interval is less than the hypothesized value, the corresponding null hypothesis will be rejected. Comparison of the performance of the two contract-free devices will be performed on the recorded results via statistical analysis. The hypothesis here is that the two devices have equivalent performance. The third test will assess the ability of the RHEA device to accurately detect motion in or exit from the bed, as compared to the manual observation. Motion and no motion accuracy will each be calculated along with their respective two-sided 95% confidence intervals.

Eligibility Criteria:
Inclusion Criteria:

1. Male or female, 18 years old and above.
2. Provide written informed consent.
3. Weight ranging from 20 to 150 kg inclusive.
4. Are located in a non-ICU hospital setting.
5. Agree to not eat during the testing period.
6. Agree to keep still.

Exclusion Criteria:

1. Are connected to a device which may interfere with the device monitoring in this study.
2. Are receiving any bedside care which may be incompatible with the study procedures.
3. Sleep apnea.
4. Pregnant or breast feeding.
5. A likely need to receive or undergo a procedure during the testing period.
6. Cannot accept a nasal cannula, or have a monitor lead placed on the chest.
7. A significant medical condition in the judgement of the investigator, which may compromise the study testing procedures.
8. Are wearing pacemaker or defibrillator.
National French Survey on Psychological Distress at Work of Anesthesia and Intensive Care Residents

Psychological distress is a significant problem for healthcare professionals and students in training. The investigator question the prevalence of this problem in French residents in anaesthesia and intensive care training.

The investigator performed an observational study on the national population of anaesthesia residents. A questionnaire was sent to all residents composed with validated questionnaires analyzing psychological distress (Hospital Anxiety and Depression Scale (HADS), Copenhagen Burnout Inventory (CBI), Perceived Stress Scale (PSS), Karasek's questionnaire; work-related questions (work hours per week, night shift per month, application of safety rest after night shift, average time to start and end work, break time and time for food per day; two semi-open work-related questions (main stressor during internship, professional orientation); a free verbatim.

Eligibility Criteria:
Inclusion Criteria:

* resident of intensive care or anesthesia, french

Exclusion Criteria:

* none
Virtual Reality and Diagnostic of Attention Deficit Hyperactivity Disorder (ADHD) (PADA1)

The aim of this study is to develop an application in order to identify the most relevant cognitive and behavioral parameters for the diagnosis of Attention Deficit Hyperactivity Disorder (ADHD) in conditions closer to reality

Attention Deficit Hyperactivity Disorder (ADHD) is the most common neurodevelopmental disorder in school-aged children. This disorder is characterized by a symptomatic triad associating, inattention, hyperactivity and impulsivity. Cognitive, emotional and behavioral dysfunctions have a strong impact on the school, family and social domains of the child. The clinical diagnosis of ADHD is all the more difficult because there are currently no biological, clinical or psychological markers that accurately measure the symptoms of ADHD. The diagnosis is made during interviews with specialist doctors allowing the collection of information from parents and the child. Virtual reality technology is most recognized as a tool for assessment, rehabilitation of cognitive processes and functional skills. In addition to traditional diagnostic assessment methods, a virtual reality application in an immersive room (CAVE) in three dimensions could objectively assess the child in a dynamic environment that is as close as possible to everyday situations

Eligibility Criteria:
Inclusion Criteria:

Group of children with ADHD :

* Children aged 8 to 12 diagnosed with ADHD (according to DSM-V criteria)
* Positive ADHD diagnosis with standardized maintenance of Kiddie-Sads
* Naïve drug treatment for ADHD
* Schooled in a classic environment
* Intellectual Quotient\> 80 (4 subtests of WASI, or WISC IV-R / WISC-V less than 2 years old)
* Having French as mother tongue
* Children benefiting from a social security scheme
* Signing of free, informed and written consent by the child and the holders of parental authority Group of children controls

Children aged 8 to 12 years undiagnosed ADHD (according to DSM-V criteria) :

* Not presenting with ADHD at standardized maintenance Kiddie-Sads
* Schooled in a classic environment
* Intellectual Quotient\> 80 (4 subtests of WASI)
* Having French as mother tongue
* Children benefiting from a social security scheme
* Signing of free, informed and written consent by the child and the holders of parental authority

Exclusion Criteria:

* Positive diagnosis with standardized maintenance of Kiddie-Sads for the following disorders: mood disorders, psychotic disorders, autism spectrum disorders, severe anxiety disorders and severe tic disorders
* Presenting a hearing or vision diagnosis diagnosed that does not allow the task to be performed in virtual reality
* Neurological disorders
* Photosensitive Epilepsy (contraindication to immersion in virtual reality)
* Treatment with psychostimulants or other psychotropic drugs
* Unable to complete the virtual reality task during the familiarization session
Can Gaming Get You Fit? A High-Intensity Exergaming Intervention in Adults

The purpose of this project is to assess if playing a newly developed videogame that require physical activity (e.g. exergame) can lead to health benefits. The project will include 50 adult participants that are not particularly physically active. They will be randomized into two groups where one group will be given free access to the exergame for 6 months. The physical fitness (maximal oxygen consumption), blood markers of cardiometabolic health and body composition of the subjects will be tested before, mid-ways and after the intervention period. Also, the participants gaming frequency will be registered throughout the 6-month period. Aim of this study is to investigate if access to this game can provide health benefits for individuals who are not motivated to take part in regular physical activity.


Eligibility Criteria:
Inclusion Criteria:

* Sedentary (\<150 mins of moderate intensity physical activity/week)
* Able to ride a bike for up to 60 minutes

Exclusion Criteria:

* Known cardiovascular disease
* Taking beta-blockers or anti-arrhythmic drugs
Effects of Oral Probiotic Product on Vaginal Microbial Community and Parameters of Vaginal Health

The purpose of the study is to assess the efficacy and safety of an oral probiotic product on the vaginal microbiome and on parameters of vaginal health. Eligible subjects will utilize the investigational product as directed for a period of 28 days. The vaginal microbial community and parameters of vaginal health will be measured at baseline and after 14 and 28 days of supplementation. A follow-up post-supplementation visit will be conducted on Day 42.


Eligibility Criteria:
Inclusion Criteria:

1. Healthy women aged 18-50 years.
2. Body mass index 18.5 - 34.9 kg/m2 (inclusive).
3. Have childbearing potential \[i.e. not surgically sterile or post-menopausal (greater than one year since last menses)\].
4. Non-smoker, or ex-smoker ≥6 months.
5. Nugent score of 4-6 or pH \>4.5
6. Agrees to maintain current level of physical activity and dietary habits throughout the trial period.
7. Agrees to discontinue use of probiotic supplements (oral or vaginal), as well as food supplemented with probiotics or prebiotics.
8. Willing and able to provide written informed consent.
9. Agrees to provide fecal samples during the trial period.

Exclusion Criteria:

1. Hypersensitivity to any ingredient in the study product.
2. Pregnancy or planning pregnancy.
3. Lactation or breast feeding.
4. Irregular menstrual cycles.
5. Use of contraceptives that contain spermicidal agents.
6. Use of an intrauterine device (IUD).
7. Use of hormonal therapy through cervical cap.
8. Use of douching devices.
9. Any major trauma or surgical event within the 3 months prior to screening.
10. Individuals undergoing therapies to prevent any recurrent infections.
11. Allergy to any antibiotic that may be prescribed as a rescue remedy during the study.
12. Use of prescription drugs (other than birth control) within 1 month prior to Visit 1.
13. Use of antibiotics within 2 months prior to Visit 1.
14. History of blood clotting disorders or use of coagulation-inhibiting drugs (e.g. warfarin)
15. Presence of systemic diseases or immunodeficiencies
16. Abdominal or gastrointestinal surgery within the previous 12 months.
17. Recent gastrointestinal food-borne illness (within 1 month prior to Visit 1)
18. History of cancer (excluding non-melanoma skin cancer and basal cell carcinoma) in the past 5 years
19. Abnormal laboratory test results of clinical significance
20. Presence or history (past 6 months) of alcohol or drug abuse
21. Subject is unwilling or unable to abide by the requirements of the protocol
22. Any condition that would interfere with the subject's ability to comply with study instructions, might confound the interpretation of the study, or put the subject at risk
23. Subject has taken an investigational health product or has participated in a research study within 30 days prior to first study visit
Evaluation of an Intervention to Increase Post-abortion LARC Uptake.

This is a randomized prospective study evaluating the impact of a brief contraceptive education intervention with optional referral for financial counseling on post abortion long-acting reversible contraceptive (LARC) uptake and contraceptive use at three months post abortion.

As repeat unintended pregnancy and abortion remain public health challenges, increasing long-acting reversible contraceptive (LARC), specifically intrauterine device (IUD) and contraceptive implant, use among women presenting for abortion care is a priority. Despite its efficacy and safety, LARC methods remain underutilized in the abortion setting.

This is a randomized prospective study evaluating the impact of a brief contraceptive education intervention with optional referral for financial counseling on post abortion long-acting reversible contraceptive (LARC) uptake and contraceptive use at three months post abortion.

Eligibility Criteria:
Inclusion Criteria:

* Women calling to schedule an appointment for an abortion and/or those who receive abortion services at the Atlanta Women's Center with fluency in English and able to provide informed consent
* 16 years and older

Exclusion Criteria:

-Younger than 16 years old
To Evaluate the Safety and PK Characteristics After Co-administration of JW0104 and C2402 and Administration of JW0105

The objective is to evaluate the safety and pharmacokinetic characteristics after co-administration of JW0104 and C2402 and administration of JW0105 in healthy volunteers under fasting conditions.

Pharmacokinetic characteristics: Describes the blood concentration statistically by pharmacokinetic blood collection time and treatment group.

Eligibility Criteria:
Inclusion Criteria:

* Healthy volunteers

Exclusion Criteria:

* Subjects does not meet the inclusion Criteria
Safety of Dialysate Sodium Individualization in Hemodialysis Patients With Intradialytic Hypotension

Low blood pressure (hypotension) during dialysis afflicts approximately 25% of hemodialysis patients. In this pilot study, we will evaluate the safety and effects of individualizing the sodium concentration in the dialysate according to the patient's own plasma sodium levels. We hypothesize that patients will have less thirst and less weight gain during the intervention leading to easier fluid removal and less episodes of hypotension.

Hypertension and intradialytic hypotension are common complications in patients on chronic maintenance hemodialysis (HD). Sodium balance is important in mediating both processes. Recent evidence shows that individualization of the sodium concentration in the dialysate to match the patient's own serum sodium results in less thirst, less interdialytic weight gain, less HD-related symptoms, and better blood pressure control. In this project we plan to evaluate the safety and tolerability of sodium individualization in hypotension-prone patients in order to generate pilot data for a larger study in patients with intradialytic hypotension. In this protocol, we will recruit 7 hypotension-prone subjects. We will use an open-label cross-over design with randomized blocks. After a 3-week baseline period where pre-HD serum sodium will be measured weekly to establish each patient's average serum sodium, subjects will be randomized to 2 weeks on standard dialysate sodium (140 mmol/L) or individualized dialysate sodium (same concentration as the average pre-HD serum sodium during the baseline period), then crossed over to the other for another 2 weeks (total study period 7 weeks, 2 weeks baseline, 4 weeks intervention). The remainder of the dialysis prescription, prescribed dry weight and vasoactive drugs will remain unchanged throughout the study. Clinical information, pre/intra/post-HD blood pressure and hemodynamics (cardiac output and systemic vascular resistance), and the frequency and severity of intradialytic symptoms related to hypotension will be collected on HD sessions during the 4 weeks of intervention.

Eligibility Criteria:
Inclusion Criteria:

* Hemodialysis patients with intradialytic hypotension

Exclusion Criteria:

* Atrial fibrillation
* Bilateral upper extremity arteriovenous access
* Average plasma sodium \>139